HilleVax Rakes in $135 Million to Rapidly Progress Norovirus Vaccine

Less than two months after spinning out of Takeda Pharmaceuticals, HilleVax, Inc. secured $135 million in crossover financing to advance the development of its Phase III-ready norovirus vaccine.